{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:33:18Z","timestamp":1793363598749,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100019690","name":"Medical Research Council Centre for Medical Mycology","doi-asserted-by":"publisher","award":["MR\/S01165X\/1"],"award-info":[{"award-number":["MR\/S01165X\/1"]}],"id":[{"id":"10.13039\/501100019690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019690","name":"Medical Research Council Centre for Medical Mycology","doi-asserted-by":"publisher","award":["MR\/S005021\/1"],"award-info":[{"award-number":["MR\/S005021\/1"]}],"id":[{"id":"10.13039\/501100019690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019690","name":"Medical Research Council Centre for Medical Mycology","doi-asserted-by":"publisher","award":["G0601943"],"award-info":[{"award-number":["G0601943"]}],"id":[{"id":"10.13039\/501100019690","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Inclusion body myositis (IBM) belongs to the group of idiopathic inflammatory myopathies and is characterized by a slowly progressive disease course with asymmetric muscle weakness of predominantly the finger flexors and knee extensors. The disease leads to severe disability and most patients lose ambulation due to lack of curative or disease-modifying treatment options. Despite some genes reported to be associated with hereditary IBM (a distinct group of conditions), data on the genetic susceptibility of sporadic IBM are very limited. This review gives an overview of the disease and focuses on the current genetic knowledge and potential therapeutic implications.<\/jats:p>","DOI":"10.1007\/s00415-022-11459-3","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T08:30:11Z","timestamp":1668760211000},"page":"1787-1797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Inclusion body myositis: from genetics to clinical trials"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6822-1609","authenticated-orcid":false,"given":"Sara","family":"Nagy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro M.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Houlden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"issue":"2","key":"11459_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/JND-160198","volume":"4","author":"A Callan","year":"2017","unstructured":"Callan A, Capkun G, Vasanthaprasad V, Freitas R, Needham M (2017) A systematic review and meta-analysis of prevalence studies of sporadic inclusion body myositis. J Neuromuscul Dis 4(2):127\u2013137","journal-title":"J Neuromuscul Dis"},{"issue":"12","key":"11459_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.jocn.2008.01.011","volume":"15","author":"M Needham","year":"2008","unstructured":"Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia FL (2008) Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 15(12):1350\u20131353","journal-title":"J Clin Neurosci"},{"issue":"21","key":"11459_CR3","doi-asserted-by":"publisher","first-page":"e2653","DOI":"10.1212\/WNL.0000000000012004","volume":"96","author":"S Shelly","year":"2021","unstructured":"Shelly S, Mielke MM, Mandrekar J, Milone M, Ernste FC, Naddaf E, Liewluck T (2021) Epidemiology and natural history of inclusion body myositis: a 40-year population-based study. Neurology 96(21):e2653\u2013e2661","journal-title":"Neurology"},{"key":"11459_CR4","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/jnnp-2020-325141","volume":"92","author":"G Sangha","year":"2021","unstructured":"Sangha G, Yao B, Lunn D, Skorupinska I, Germain L, Kozyra D, Parton M, Miller J, Hanna MG, Hilton-Jones D, Freebody J, Machado PM (2021) Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis. J Neurol Neurosurg Psychiatry 92:854\u2013862","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"11459_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1055\/s-0032-1329197","volume":"32","author":"MM Dimachkie","year":"2012","unstructured":"Dimachkie MM, Barohn RJ (2012) Inclusion body myositis. Semin Neurol 32(3):237\u2013245","journal-title":"Semin Neurol"},{"issue":"5","key":"11459_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.nmd.2013.02.010","volume":"23","author":"A Cortese","year":"2013","unstructured":"Cortese A, Machado P, Morrow J, Dewar L, Hiscock A, Miller A, Brady S, Hilton-Jones D, Parton M, Hanna MG (2013) Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul Disord 23(5):404\u2013412","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"11459_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","volume":"15","author":"SA Greenberg","year":"2019","unstructured":"Greenberg SA (2019) Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol 15(5):257\u2013272","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"11459_CR8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/01.bor.0000434671.77891.9a","volume":"25","author":"P Machado","year":"2013","unstructured":"Machado P, Brady S, Hanna MG (2013) Update in inclusion body myositis. Curr Opin Rheumatol 25(6):763\u2013771","journal-title":"Curr Opin Rheumatol"},{"key":"11459_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27716","author":"M Alamr","year":"2022","unstructured":"Alamr M, Pinto MV, Naddaf E (2022) Atypical presentations of inclusion body myositis: clinical characteristics and long-term outcomes. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.27716 (Epub ahead of print)","journal-title":"Muscle Nerve"},{"issue":"5","key":"11459_CR10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","volume":"83","author":"TE Lloyd","year":"2014","unstructured":"Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA (2014) Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 83(5):426\u2013433","journal-title":"Neurology"},{"issue":"2","key":"11459_CR11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.55563\/clinexprheumatol\/r625rm","volume":"40","author":"S Salam","year":"2022","unstructured":"Salam S, Dimachkie MM, Hanna MG, Machado PM (2022) Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis. Clin Exp Rheumatol 40(2):384\u2013393","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"11459_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/acn3.51294","volume":"8","author":"C Ikenaga","year":"2021","unstructured":"Ikenaga C, Findlay AR, Goyal NA, Robinson S, Cauchi J, Hussain Y, Wang LH, Kershen JC, Beson BA, Wallendorf M, Bucelli RC, Mozaffar T, Pestronk A, Weihl CC (2021) Clinical utility of anti-cytosolic 5\u2019-nucleotidase 1A antibody in idiopathic inflammatory myopathies. Ann Clin Transl Neurol 8(3):571\u2013578","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"11459_CR13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ncl.2020.03.014","volume":"38","author":"V Vivekanandam","year":"2020","unstructured":"Vivekanandam V, Bugiardini E, Merve A, Parton M, Morrow JM, Hanna MG, Machado PM (2020) Differential diagnoses of inclusion body myositis. Neurol Clin 38(3):697\u2013710","journal-title":"Neurol Clin"},{"issue":"5","key":"11459_CR14","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/WCO.0000000000000740","volume":"32","author":"J Tanboon","year":"2019","unstructured":"Tanboon J, Nishino I (2019) Classification of idiopathic inflammatory myopathies: pathology perspectives. Curr Opin Neurol 32(5):704\u2013714","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"11459_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/WCO.0000000000001095","volume":"35","author":"M Perez-Rosendahl","year":"2022","unstructured":"Perez-Rosendahl M, Mozaffar T (2022) Inclusion body myositis: evolving concepts. Curr Opin Neurol 35(5):604\u2013610","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"11459_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00401-015-1384-5","volume":"129","author":"O Benveniste","year":"2015","unstructured":"Benveniste O, Stenzel W, Hilton-Jones D, Sandri M, Boyer O, van Engelen BG (2015) Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol 129(5):611\u2013624","journal-title":"Acta Neuropathol"},{"issue":"1","key":"11459_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/biom9010015","volume":"9","author":"B De Paepe","year":"2019","unstructured":"De Paepe B (2019) Sporadic inclusion body myositis: an acquired mitochondrial disease with extras. Biomolecules 9(1):15","journal-title":"Biomolecules"},{"issue":"5","key":"11459_CR18","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/art.40045","volume":"69","author":"S Rothwell","year":"2017","unstructured":"Rothwell S, Cooper RG, Lundberg IE, Gregersen PK, Hanna MG, Machado PM, Herbert MK, Pruijn GJ, Lilleker JB, Roberts M, Bowes J (2017) Immune-array analysis in sporadic inclusion body myositis reveals HLA\u2013DRB1 amino acid heterogeneity across the myositis spectrum. Arthritis Rheumatol 69(5):1090\u20131099","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"11459_CR19","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1136\/annrheumdis-2015-208119","volume":"75","author":"S Rothwell","year":"2016","unstructured":"Rothwell S, Cooper RG, Lundberg IE, Miller FW, Gregersen PK, Bowes J, Vencovsky J, Danko K, Limaye V, Selva-O\u2019Callaghan A, Hanna MG (2016) Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis 75(8):1558\u20131566","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"11459_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12931","volume":"31","author":"C Hedberg-Oldfors","year":"2021","unstructured":"Hedberg-Oldfors C, Lindgren U, Basu S, Visuttijai K, Lindberg C, Falkenberg M, Larsson Lekholm E, Oldfors A (2021) Mitochondrial DNA variants in inclusion body myositis characterized by deep sequencing. Brain Pathol 31(3):e12931","journal-title":"Brain Pathol"},{"issue":"11","key":"11459_CR21","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1093\/nar\/gkw382","volume":"44","author":"KA Rygiel","year":"2016","unstructured":"Rygiel KA, Tuppen HA, Grady JP, Vincent A, Blakely EL, Reeve AK, Taylor RW, Picard M, Miller J, Turnbull DM (2016) Complex mitochondrial DNA rearrangements in individual cells from patients with sporadic inclusion body myositis. Nucleic Acids Res 44(11):5313\u20135329","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"11459_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/nan.12149","volume":"41","author":"KA Rygiel","year":"2015","unstructured":"Rygiel KA, Miller J, Grady JP, Rocha MC, Taylor RW, Turnbull DM (2015) Mitochondrial and inflammatory changes in sporadic inclusion body myositis. Neuropathol Appl Neurobiol 41(3):288\u2013303","journal-title":"Neuropathol Appl Neurobiol"},{"key":"11459_CR23","doi-asserted-by":"publisher","first-page":"1766.e1","DOI":"10.1016\/j.neurobiolaging.2014.12.039","volume":"36","author":"Q Gang","year":"2015","unstructured":"Gang Q, Bettencourt C, Machado PM, Fox Z, Brady S, Healy E et al (2015) The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. Neurobiol Aging 36:1766.e1-1766.e3","journal-title":"Neurobiol Aging"},{"issue":"2","key":"11459_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.24847","volume":"81","author":"AK G\u00fcttsches","year":"2017","unstructured":"G\u00fcttsches AK, Brady S, Krause K, Maerkens A, Uszkoreit J, Eisenacher M, Schreiner A, Galozzi S, Mertens-Rill J, Tegenthoff M, Holton JL, Harms MB, Lloyd TE, Vorgerd M, Weihl CC, Marcus K, Kley RA (2017) Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Ann Neurol 81(2):227\u2013239","journal-title":"Ann Neurol"},{"issue":"4","key":"11459_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.nmd.2014.12.009","volume":"25","author":"CC Weihl","year":"2015","unstructured":"Weihl CC, Baloh RH, Lee Y, Chou TF, Pittman SK, Lopate G, Allred P, Jockel-Balsarotti J, Pestronk A, Harms MB (2015) Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. Neuromuscul Disord 25(4):289\u2013296","journal-title":"Neuromuscul Disord"},{"issue":"47","key":"11459_CR26","first-page":"218","volume":"1","author":"Q Gang","year":"2016","unstructured":"Gang Q, Bettencourt C, Machado PM, Brady S, Holton JL, Pittman AM, Hughes D, Healy E, Parton M, Hilton-Jones D, Shieh PB (2016) Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. Neurobiol Aging 1(47):218-e1","journal-title":"Neurobiol Aging"},{"key":"11459_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1750-1172-9-88","volume":"9","author":"Q Gang","year":"2014","unstructured":"Gang Q, Bettencourt C, Machado P, Hanna MG, Houlden H (2014) Sporadic inclusion body myositis: the genetic contributions to the pathogenesis. Orphanet J Rare Dis 9:88","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"11459_CR28","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/ene.13244","volume":"24","author":"M Johari","year":"2017","unstructured":"Johari M, Arumilli M, Palmio J, Savarese M, Tasca G, Mirabella M, Sandholm N, Lohi H, Hackman P, Udd B (2017) Association study reveals novel risk loci for sporadic inclusion body myositis. Eur J Neurol 24(4):572\u2013577","journal-title":"Eur J Neurol"},{"issue":"6","key":"11459_CR29","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/BOR.0000000000000431","volume":"29","author":"S Rothwell","year":"2017","unstructured":"Rothwell S, Lilleker JB, Lamb JA (2017) Genetics in inclusion body myositis. Curr Opin Rheumatol 29(6):639\u2013644","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"11459_CR30","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/s41588-021-00921-z","volume":"53","author":"DP Wightman","year":"2021","unstructured":"Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, Rongve A, B\u00f8rte S, Winsvold BS, Drange OK, Martinsen AE (2021) A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer\u2019s disease. Nat Genet 53(9):1276\u201382","journal-title":"Nat Genet"},{"issue":"2\u20133","key":"11459_CR31","doi-asserted-by":"publisher","first-page":"J129","DOI":"10.1016\/j.jaut.2011.10.004","volume":"38","author":"SP Dillon","year":"2012","unstructured":"Dillon SP, Kurien BT, Li S, Bruner GR, Kaufman KM, Harley JB, Gaffney PM, Wallace DJ, Weisman MH, Scofield RH (2012) Sex chromosome aneuploidies among men with systemic lupus erythematosus. J Autoimmun 38(2\u20133):J129-34","journal-title":"J Autoimmun"},{"issue":"168","key":"11459_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.clim.2016.04.002","volume":"1","author":"VM Harris","year":"2016","unstructured":"Harris VM, Sharma R, Cavett J, Kurien BT, Liu K, Koelsch KA, Rasmussen A, Radfar L, Lewis D, Stone DU, Kaufman CE (2016) Klinefelter\u2019s syndrome (47, XXY) is in excess among men with Sj\u00f6gren\u2019s syndrome. Clin Immunol 1(168):25\u20139","journal-title":"Clin Immunol"},{"issue":"13","key":"11459_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886290","volume":"26","author":"JA Lamb","year":"2022","unstructured":"Lamb JA (2022) The genetics of autoimmune myositis. Front Immunol 26(13):886290","journal-title":"Front Immunol"},{"issue":"6","key":"11459_CR34","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/acr2.11413","volume":"4","author":"RH Scofield","year":"2022","unstructured":"Scofield RH, Lewis VM, Cavitt J, Kurien BT, Assassi S, Martin J, Gorlova O, Gregersen P, Lee A, Rider LG, Oanlon T, Rothwell S, Lilleker J, Myositis Genetics Consortium, Xiaoxi L, Kochi Y, Terao C, Igoe A, Stevens W, Sahhar J, Roddy J, Rischmueller M, Lester S, Proudman S, Chen S, Brown MA, Mayes MD, Lamb JA, Miller FW (2022) 47XXY and 47XXX in Scleroderma and Myositis. ACR Open Rheumatol. 4(6):528\u2013533","journal-title":"ACR Open Rheumatol."},{"issue":"4","key":"11459_CR35","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/ard.2004.025494","volume":"64","author":"B Ranque-Francois","year":"2005","unstructured":"Ranque-Francois B, Maisonobe T, Dion E, Piette JC, Chauveheid MP, Amoura Z, Papo T (2005) Familial inflammatory inclusion body myositis. Ann Rheum Dis 64(4):634\u20137","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"11459_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/mus.20766","volume":"35","author":"M Needham","year":"2007","unstructured":"Needham M, Mastaglia FL, Garlepp MJ (2007) Genetics of inclusion-body myositis. Muscle Nerve 35(5):549\u201361","journal-title":"Muscle Nerve"},{"issue":"1","key":"11459_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/ng718","volume":"29","author":"I Eisenberg","year":"2001","unstructured":"Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, Olender T, Barash M, Shemesh M, Sadeh M, Grabov-Nardini G, Shmilevich I, Friedmann A, Karpati G, Bradley WG, Baumbach L, Lancet D, Asher EB, Beckmann JS, Argov Z, Mitrani-Rosenbaum S (2001) The UDP-N-acetylglucosamine 2-epimerase\/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 29(1):83\u20137","journal-title":"Nat Genet"},{"issue":"11","key":"11459_CR38","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1212\/01.WNL.0000041631.28557.C6","volume":"59","author":"I Nishino","year":"2002","unstructured":"Nishino I, Noguchi S, Murayama K, Driss A, Sugie K, Oya Y, Nagata T, Chida K, Takahashi T, Takusa Y, Ohi T, Nishimiya J, Sunohara N, Ciafaloni E, Kawai M, Aoki M, Nonaka I (2002) Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology 59(11):1689\u201393","journal-title":"Neurology"},{"issue":"4","key":"11459_CR39","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.bbadis.2014.08.007","volume":"1852","author":"A Broccolini","year":"2015","unstructured":"Broccolini A, Mirabella M (2015) Hereditary inclusion-body myopathies. Biochim Biophys Acta 1852(4):644\u201350","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"11459_CR40","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/1531-8249(200006)47:6<811::AID-ANA16>3.0.CO;2-9","volume":"47","author":"C Di Blasi","year":"2000","unstructured":"Di Blasi C, Mora M, Pareyson D, Farina L, Sghirlanzoni A, Vignier N, Blasevich F, Cornelio F, Guicheney P, Morandi L (2000) Partial laminin alpha2 chain deficiency in a patient with myopathy resembling inclusion body myositis. Ann Neurol 47(6):811\u20136","journal-title":"Ann Neurol"},{"issue":"7442","key":"11459_CR41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature11922","volume":"495","author":"HJ Kim","year":"2013","unstructured":"Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, MacLea KS, Freibaum B, Li S, Molliex A, Kanagaraj AP, Carter R, Boylan KB, Wojtas AM, Rademakers R, Pinkus JL, Greenberg SA, Trojanowski JQ, Traynor BJ, Smith BN, Topp S, Gkazi AS, Miller J, Shaw CE, Kottlors M, Kirschner J, Pestronk A, Li YR, Ford AF, Gitler AD, Benatar M, King OD, Kimonis VE, Ross ED, Weihl CC, Shorter J, Taylor JP (2013) Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495(7442):467\u201373","journal-title":"Nature"},{"issue":"6","key":"11459_CR42","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/ejhg.2013.250","volume":"22","author":"H Tajsharghi","year":"2014","unstructured":"Tajsharghi H, Hammans S, Lindberg C, Lossos A, Clarke NF, Mazanti I, Waddell LB, Fellig Y, Foulds N, Katifi H, Webster R, Raheem O, Udd B, Argov Z, Oldfors A (2014) Recessive myosin myopathy with external ophthalmoplegia associated with MYH2 mutations. Eur J Hum Genet 22(6):801\u20138","journal-title":"Eur J Hum Genet"},{"issue":"628","key":"11459_CR43","doi-asserted-by":"publisher","first-page":"eabi1196","DOI":"10.1126\/scitranslmed.abi9196","volume":"14","author":"KA Britson","year":"2022","unstructured":"Britson KA, Ling JP, Braunstein KE, Montagne JM, Kastenschmidt JM, Wilson A, Ikenaga C, Tsao W, Pinal-Fernandez I, Russell KA, Reed N, Mozaffar T, Wagner KR, Ostrow LW, Corse AM, Mammen AL, Villalta SA, Larman HB, Wong PC, Lloyd TE (2022) Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Sci Transl Med. 14(628):eabi1196","journal-title":"Sci Transl Med."},{"issue":"2","key":"11459_CR44","first-page":"43","volume":"10","author":"R Aggarwal","year":"2012","unstructured":"Aggarwal R, Oddis CV (2012) Inclusion body myositis: therapeutic approaches. Degener Neurol Neuromuscul Dis 10(2):43\u201352","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"Pt 6","key":"11459_CR45","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/brain\/awp104","volume":"132","author":"MC Dalakas","year":"2009","unstructured":"Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, Shrader JA, Levy EW, Dambrosia J, Kampen RL, Bruno DA, Kirk AD (2009) Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132(Pt 6):1536\u201344","journal-title":"Brain"},{"issue":"2","key":"11459_CR46","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1212\/01.WNL.0000071852.27182.C7","volume":"61","author":"C Lindberg","year":"2003","unstructured":"Lindberg C, Trysberg E, Tarkowski A, Oldfors A (2003) Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 61(2):260\u20132","journal-title":"Neurology"},{"issue":"3","key":"11459_CR47","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"MC Dalakas","year":"1997","unstructured":"Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48(3):712\u20136","journal-title":"Neurology"},{"issue":"7","key":"11459_CR48","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","volume":"58","author":"SB Rutkove","year":"2002","unstructured":"Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM (2002) A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 58(7):1081\u20137","journal-title":"Neurology"},{"issue":"suppl 9","key":"11459_CR49","first-page":"1008","volume":"73","author":"N Goel","year":"2021","unstructured":"Goel N, Soler-Ferran D, Coutreau M, Escobar J, Courtemanche K, Needham M, Greenberg S (2021) Depletion of KLRG1+ T cells in a first-in-human clinical trial of ABC008 in inclusion body myositis (IBM) [abstract]. Arthritis Rheumatol 73(suppl 9):1008\u20131009","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"11459_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11926-018-0738-0","volume":"20","author":"KA Britson","year":"2018","unstructured":"Britson KA, Yang SY, Lloyd TE (2018) New developments in the genetics of inclusion body myositis. Curr Rheumatol Rep 20(5):26","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"11459_CR51","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","volume":"25","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, Berry K, Miller N, Yalvac M, Dvorchik I, Moore-Clingenpeel M, Flanigan KM, Church K, Shontz K, Curry C, Lewis S, McColly M, Hogan MJ, Kaspar BK (2017) Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Mol Ther 25(4):870\u2013879","journal-title":"Mol Ther"},{"key":"11459_CR52","doi-asserted-by":"crossref","unstructured":"Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, Aoki M, Machado PM, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Katsuno M, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Auberson LZ, Wu M, de Vera A, Papanicolaou DA, Amato AA; RESILIENT Study Group (2019) Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol 18(9):834\u2013844","DOI":"10.1016\/S1474-4422(19)30200-5"},{"key":"11459_CR53","doi-asserted-by":"crossref","unstructured":"Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tank\u00f3 LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; RESILIENT Study Extension Group (2021). Efficacy and Safety of bimagrumab in sporadic inclusion body myositis: long-term extension of RESILIENT. Neurology 96(12):e1595\u2013e1607","DOI":"10.1212\/WNL.0000000000011626"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11459-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11459-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11459-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T13:06:28Z","timestamp":1677503188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11459-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["11459"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11459-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"assertion":[{"value":"17 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"PMM has received honoraria from Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB. The other authors have no conflict of interest related to this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}